Striverdi Respimat
(Olodaterol)ApprovedSmall molecule
Boehringer IngelheimStriverdi Respimat is a small molecule that works as a Beta-2 Adrenergic Receptor Agonist.[2] It is being used across 6 indications, with its most advanced program in Approved.[1]
Striverdi Respimat is one of 145 small molecule programs targeting Airway obstruction. It is currently in Approved.
6
Indications
35
Total Trials
0
Active Trials
144
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Striverdi Respimat
Boehringer IngelheimApproved
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Symbicort
AstraZenecaPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease12 trials
Show 9 more trials
Asthma5 trials
COPD5 trials
Exercise2 trials
7 more indications
Function1 trial
Salmeterol1 trial
Physical Activity1 trial
Corticosteroids1 trial
Regulatory
FDA Approval Timeline[4]
Jul 31, 2014
STRIVERDI RESPIMAT
NDA NDA203108
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olodaterol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company